Offer Talks Terminated

Oxford Biomedica PLC
07 February 2005



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')


Termination of discussions


On 19 January 2005 the Board of Oxford BioMedica announced that it had received
an approach from a third party regarding a potential merger, which may or may
not lead to an offer for the Company.


The Board of Oxford BioMedica announces that the discussions that followed this
unsolicited approach have terminated.


7 February 2005


Enquiries:


Oxford BioMedica plc                                   Tel: [phone]
Professor Alan Kingsman, Chief Executive Officer

Rothschild                                             Tel: [phone]
Dr. Lynn Drummond


N M Rothschild & Sons Limited ('Rothschild'), which is authorised and regulated
by the Financial Services Authority in the United Kingdom, acts for Oxford
BioMedica plc and no one else in relation to the contents of this announcement
and will not be responsible to anyone other than Oxford BioMedica plc for
providing the protections afforded to clients of Rothschild nor for providing
advice in relation to the contents of this announcement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange